<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02899169</url>
  </required_header>
  <id_info>
    <org_study_id>APL16</org_study_id>
    <nct_id>NCT02899169</nct_id>
  </id_info>
  <brief_title>Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)</brief_title>
  <official_title>Treatment of Non-high-risk Acute Promyelocytic Leukemia With Realgar-Indigo Naturalis Formula (RIF) and All-trans Retinoid Acid (ATRA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators design a multicenter randomized controlled trial to prove that RIF plus
      ATRA is possibly superior to ATO plus ATRA as consolidation and maintenance treatment for the
      patients with non-high-risk APL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML) which
      accounts for 10-15% of acute myeloid leukemia. It is characterized by the PML-RARA fusion
      gene generated by the t(15;17)(q22;q21) chromosomal translocation. The application of ATRA
      and ATO, make APL from highly fatal to highly curable. APL0406 study proves that ATRA plus
      arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in
      the treatment of patients with non-high-risk APL. Now, the arsenic trioxide has already
      became the based regimen as targeted first-line treatment without chemotherapy. A study shows
      that oral RIF plus ATRA is not inferior to intravenous ATO plus ATRA as maintenance treatment
      of APL. The investigators design a multicenter randomized controlled trial to prove that RIF
      plus ATRA is possibly superior to ATO plus ATRA as consolidation and maintenance treatment
      for the patients with non-high-risk APL. Application of oral RIF decrease the total
      hospitalization days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>At 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of overall survival (OS)</measure>
    <time_frame>At 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>From date of randomization until the date of first documented event, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cumulative incidence of relapse (CIR)</measure>
    <time_frame>assessed up to 3 years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hematological and non-hematological toxicity</measure>
    <time_frame>From date of randomization until 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medical expense</measure>
    <time_frame>From date of randomization until 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospitalization days during therapy</measure>
    <time_frame>At 2 years from study entry</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Acute Promyelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Oral Realgar-Indigo naturalis formula(RIF) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease &lt;10x109/L. Consolidation therapy: RIF（60mg/kg/d) and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: RIF and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Arsenic Trioxide(ATO) Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease &lt;10x109/L. Consolidation therapy: ATO and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: ATO and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Realgar-Indigo naturalis formula</intervention_name>
    <arm_group_label>Oral Realgar-Indigo naturalis formula(RIF) Group</arm_group_label>
    <other_name>RIF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>all-trans retinoic acid</intervention_name>
    <arm_group_label>Oral Realgar-Indigo naturalis formula(RIF) Group</arm_group_label>
    <arm_group_label>Intravenous Arsenic Trioxide(ATO) Group</arm_group_label>
    <other_name>ATRA</other_name>
    <other_name>Tretinoin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic trioxide</intervention_name>
    <arm_group_label>Intravenous Arsenic Trioxide(ATO) Group</arm_group_label>
    <other_name>ATO</other_name>
    <other_name>Trisenox (R)</other_name>
    <other_name>As2O3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <arm_group_label>Oral Realgar-Indigo naturalis formula(RIF) Group</arm_group_label>
    <arm_group_label>Intravenous Arsenic Trioxide(ATO) Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 14 to 70 years

          -  Newly diagnosed APL with t(15;17)(q22;q12)

          -  Before treatment the Peripheral blood white blood cell count＜40×109/L

          -  Patients who can complete the entire treatment process

          -  Patients or their families signed written informed consent

        Exclusion Criteria:

          -  Be allergic to the drug ingredient, the supplementary material or the allergic
             constitution person

          -  Cardiac insufficiency, renal insufficiency, significant arrhythmias, EKG abnormalities
             or other important organ dysfunction

          -  Combined with other malignant tumors

          -  Pregnant and lactating women

          -  Participants in other drug trials in the last 3 months

          -  Suffering from mental illness or other circumstances which unable to carry out the
             plan

          -  Other patients who were not suitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Lu, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huaiyu Wang, Dr.</last_name>
    <phone>15809207527</phone>
    <email>whymed@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huaiyu Wang, Dr.</last_name>
      <phone>15809207527</phone>
      <email>whymed@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874.</citation>
    <PMID>23841729</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, Jiang H, Chen SJ, Huang XJ. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013 Nov 20;31(33):4215-21. doi: 10.1200/JCO.2013.48.8312. Epub 2013 Oct 14.</citation>
    <PMID>24127444</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhu HH, Huang XJ. Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia. N Engl J Med. 2014 Dec 4;371(23):2239-41. doi: 10.1056/NEJMc1412035.</citation>
    <PMID>25470713</PMID>
  </results_reference>
  <results_reference>
    <citation>Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol. 2017 Feb 20;35(6):605-612. doi: 10.1200/JCO.2016.67.1982. Epub 2016 Oct 31.</citation>
    <PMID>27400939</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute promyelocytic leukemia</keyword>
  <keyword>Realgar-Indigo Naturalis Formula</keyword>
  <keyword>All-trans Retinoic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic trioxide</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

